MedTrace Logo

Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

NCT04339127 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-04-09

No results posted yet for this study

Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.

One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.

The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Conditions

  • Autoimmune Encephalitis
  • Anti NMDA Receptor Encephalitis
  • Herpetic Encephalitis

Interventions

OTHER

Description and analysis

Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Jérôme Honnorat · National Reference Center of autoimmune encephalitis

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-06-01
Completion
2020-10-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04339127 on ClinicalTrials.gov